Boston Scientific is flexing its financial muscles with a strong 16.6% year-to-date gain, easily outpacing the 5.6% return of ...

Get Boston vs Los Angeles baseball betting preview, spread and over/under insights for their matchup on June 4.

Shares of Boston Scientific Corp. BSX slid 1.03% to $103.10 Tuesday, on what proved to be an all-around positive trading ...

The FDA approved treprostinil (Yutrepia) inhalation powder for pulmonary arterial hypertension and pulmonary hypertension ...

Even though the growth of Massachusetts' life sciences industry has slowed down and faces looming federal funding challenges, ...

Boston Scientific Corp. closed 2.80% short of its 52-week high of $107.17, which the company achieved on February 5th.

Boston Scientific has pulled global sales of, and is no longer seeking FDA approval for, its Acurate neo2 and Acurate Prime aortic valve systems. In a May 28 Securities and Exchange Commission filing, ...

The company also shared more details of its exit from the TAVR market and the impact of FDA layoffs on product review times.

Boston Scientific’s retreat from selling its ACURATE heart valves and halting FDA approval efforts created mild ripples in ...

Boston Scientific has discontinued global sales of its Acurate neo2 and Acurate Prime transcatheter aortic valve replacement ...

Boston Scientific Corp. reported the latest setback in its transcatheter aortic valve replacement (TAVR) aspirations with the ...

Boston Scientific will eliminate jobs after discontinuing global sales of its Acurate aortic valve replacement systems that ...